Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial (Publication with Expression of Concern. See vol. 112, pg. 1406, 2020) (Retracted article. See vol. 113, pg. 1382, 2021)
Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial (Publication with Expression of Concern. See vol. 112, pg. 1406, 2020) (Retracted article. See vol. 113, pg. 1382, 2021)
复制标题
DOI：
10.3945/ajcn.113.072785
复制
发表时间：
2013-12-01
影响因子：
7.1
通讯作者：
Esmaillzadeh, Ahmad
中科院分区：
文献类型：
--
作者：
Asemi, Zatollah;Hashemi, Teibeh;Esmaillzadeh, Ahmad
背景：据我们所知，目前还没有研究表明补充维生素D对妊娠期糖尿病（GDM）代谢状态的影响。目的：本研究旨在评估补充维生素D对妊娠期糖尿病孕妇代谢谱、高敏c反应蛋白和氧化应激生物标志物的影响。设计：这项随机、双盲、安慰剂对照的临床试验在54名患有GDM的女性中进行。受试者被随机分配服用维生素D补充剂或安慰剂。维生素D组（n = 27）的个体在研究期间（基线和干预的第21天）接受了2次含有50,000 IU维生素D-3的胶囊，而安慰剂组（n = 27）的个体同时接受了2种安慰剂。在基线和干预6周后收集空腹血液样本以量化相关变量。结果：与安慰剂相比，补充胆钙化醇导致血清25-羟基维生素D浓度增加（+18.5 +/- 20.4 ng/mL与+0.5 +/- 6.1 ng/mL相比，P < 0.001）。此外，维生素D补充剂的摄入导致空腹血糖（-17.1 +/- 14.8 mg/dL，与-0.9 +/- 16.6 mg/dL相比，P < 0.001）和血清胰岛素（-3.08 +/- 6.62，与+1.34 +/- 6.51 mu IU/mL相比，P = 0.01）和评估胰岛素抵抗的稳态模型(-1.28 +/- 1.41，与+0.34 +/- 1.79；P < 0.001)，定量胰岛素敏感性检查指数与安慰剂相比显著增加（+0.03 +/- 0.03与-0.001 +/- 0.02相比，P = 0.003）。总浓度显著降低（-11.0 +/- 23.5 mg/dL与+9.5 +/- 36.5 mg/dL相比；P = 0.01）和低密度。脂蛋白（LDL） （-10.8 +/- 22.4 mg/dL与+10.4 +/- 28.0 mg/dL相比，P = 0.003）胆固醇也在补充维生素D后出现。结论：妊娠期糖尿病孕妇补充维生素D对血糖、总胆固醇和低密度脂蛋白胆固醇浓度有有益影响，但对炎症和氧化应激没有影响。
Background: To our knowledge, there is no study that has examined the effects of vitamin D supplementation on metabolic status in gestational diabetes mellitus (GDM).Objective: This study was designed to assess the effects of vitamin D supplementation on metabolic profiles, high-sensitivity C-reactive protein, and biomarkers of oxidative stress in pregnant women with GDM.Design: This randomized, double-blind, placebo-controlled clinical trial was conducted in 54 women with GDM. Subjects were randomly assigned to receive either vitamin D supplements or placebo. Individuals in the vitamin D group (n = 27) received capsules containing 50,000 IU vitamin D-3 2 times during the study (at baseline and at day 21 of the intervention) and those in the placebo group (n = 27) received 2 placebos at the same times. Fasting blood samples were collected at baseline and after 6 wk of the intervention to quantify relevant variables.Results: Cholecalciferol supplementation resulted in increased serum 25-hydroxyvitamin D concentrations compared with placebo (+18.5 +/- 20.4 compared with +0.5 +/- 6.1 ng/mL; P < 0.001). Furthermore, intake of vitamin D supplements led to a significant decrease in concentrations of fasting plasma glucose (-17.1 +/- 14.8 compared with -0.9 +/- 16.6 mg/dL; P < 0.001) and serum insulin (-3.08 +/- 6.62 compared with +1.34 +/- 6.51 mu IU/mL; P = 0.01) and homeostasis model of assessment-insulin resistance (-1.28 +/- 1.41 compared with +0.34 +/- 1.79; P < 0.001) and a significant increase in the Quantitative Insulin Sensitivity Check Index (+0.03 +/- 0.03 compared with -0.001 +/- 0.02; P = 0.003) compared with placebo. A significant reduction in concentrations of total (-11.0 +/- 23.5 compared with +9.5 +/- 36.5 mg/dL; P = 0.01) and low-density. lipoprotein (LDL) (-10.8 +/- 22.4 compared with +10.4 +/- 28.0 mg/dL; P = 0.003) cholesterol was also seen after vitamin D supplementation.Conclusions: Vitamin D supplementation in pregnant women with GDM had beneficial effects on glycemia and total and LDL-cholesterol concentrations but did not affect inflammation and oxidative stress.